These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 20874249)

  • 21. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    J Neurol Sci; 2007 Aug; 259(1-2):27-37. PubMed ID: 17391705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies in the treatment of multiple sclerosis.
    Di Pauli F; Berger T; Reindl M
    Curr Med Chem; 2009; 16(36):4858-68. PubMed ID: 19929782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Multiple sclerosis: current therapies and future perspectives].
    Matsushita T
    Nihon Rinsho; 2011 Nov; 69(11):2077-86. PubMed ID: 22111333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and future therapies targeting the immune system in multiple sclerosis.
    Loleit V; Biberacher V; Hemmer B
    Curr Pharm Biotechnol; 2014; 15(3):276-96. PubMed ID: 24938888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease modifying therapies for relapsing multiple sclerosis.
    Wingerchuk DM; Weinshenker BG
    BMJ; 2016 Aug; 354():i3518. PubMed ID: 27549763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Newer agents in the treatment of multiple sclerosis.
    Pawate S; Bagnato F
    Neurologist; 2015 Apr; 19(4):104-17. PubMed ID: 25888198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Interferon beta treatment in multiple sclerosis].
    Ochi H
    Nihon Rinsho; 2003 Aug; 61(8):1367-73. PubMed ID: 12962025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction and escalation therapies in multiple sclerosis.
    Fenu G; Lorefice L; Frau F; Coghe GC; Marrosu MG; Cocco E
    Antiinflamm Antiallergy Agents Med Chem; 2015; 14(1):26-34. PubMed ID: 25938688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and future therapies for multiple sclerosis.
    Minagar A
    Scientifica (Cairo); 2013; 2013():249101. PubMed ID: 24278770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?
    Kappos L; Kuhle J; Gass A; Achtnichts L; Radue EW
    J Neurol; 2004 Sep; 251 Suppl 5():v57-v64. PubMed ID: 15549357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging therapies in multiple sclerosis.
    Farrell R; Heaney D; Giovannoni G
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):797-816. PubMed ID: 16262563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
    Pittock SJ; Rodriguez M
    Curr Top Microbiol Immunol; 2008; 318():1-17. PubMed ID: 18219812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects.
    Pender MP; Wolfe NP
    Intern Med J; 2002 Nov; 32(11):554-63. PubMed ID: 12412939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current disease-modifying treatment of multiple sclerosis.
    Derwenskus J
    Mt Sinai J Med; 2011; 78(2):161-75. PubMed ID: 21425262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.
    Freedman MS
    Eur J Neurol; 2014 Mar; 21(3):377-87, e18-20. PubMed ID: 24237582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Disease-modifying treatments in multiple sclerosis].
    Confavreux C; Bouhour F; Vukusic S
    Rev Prat; 1999 Nov; 49(17):1882-9. PubMed ID: 10598505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.